Catapres TabletsOut of date information, search another
Catapres Tablets 100 micrograms.
Each tablet contains 100 micrograms of clonidine hydrochloride. For excipients see 6.1.
White, circular, flat, bevel-edged tablets impressed with the identifying code on one side and the company symbol on the reverse.
Catapres is indicated for the treatment of all grades of essential and secondary hypertension.
Catapres Tablets are for oral administration only.
Oral treatment should commence with 50 - 100 micrograms three times daily. This dose should be increased gradually every second or third day until control is achieved. Most patients will be controlled on divided daily doses of 300 - 1200 micrograms. However, some patients may require higher doses, e.g. 1800 micrograms or more.
Catapres may be added to an existing antihypertensive regimen where blood pressure control has not been satisfactorily achieved. If side-effects with existing therapy are troublesome the concomitant use of Catapres may allow a lower dose of the established regimen to be employed. Patients changing treatment should have their existing therapy reduced gradually whilst Catapres is added to their regimen.
Patients undergoing anaesthesia should continue their Catapres treatment before, during and after anaesthesia using oral or i.v. administration according to individual circumstances.
No specific information on the use of this product in the elderly is available. Clinical trials have included patients over 65 years and no adverse reactions specific to this age group have been reported.
There is insufficient evidence for the application of clonidine in children and adolescents younger than 18 years. Therefore the use of clonidine is not recommended in paediatric subjects under 18 years.
Patients with renal impairment:
Dosage must be adjusted
- according to the individual antihypertensive response which can show high variability in patients with renal insufficiency, careful monitoring is required (See Section 4.4)
- according to the degree of renal impairment
Catapres should not be used in patients with known hypersensitivity to the active ingredient or other components of the product, and in patients with severe bradyarrhythmia resulting from either sick sinus syndrome or AV block of 2nd or 3rd degree.
In case of rare hereditary conditions that may be incompatible with an excipient of the product (please refer to section 4.4 Special Warnings and Precautions for Use) the use of the product is contraindicated.
Caution should be exercised in patients with Raynaud's disease or other peripheral vascular disease. As with all drugs used in hypertension Catapres should be used with caution in patients with cerebrovascular or coronary insufficiency.
Catapres should also be used with caution in patients with mild to moderate bradyarrhythmia such as low sinus rhythm, and with polyneuropathy or constipation.
Patients with a known history of depression should be carefully supervised while under long-term treatment with Catapres as there have been occasional reports of further depressive episodes during oral treatment in such patients.
As with other antihypertensive drugs, treatment with Catapres should be monitored particularly carefully in patients with heart failure.
In hypertension caused by phaeochromocytoma no therapeutic effect of Catapres can be expected.
Clonidine, the active ingredient of Catapres, and its metabolites are extensively excreted in the urine. Dosage must be adjusted to the individual antihypertensive response, which can show high variability in patients with renal insufficiency (See Section 4.2); careful monitoring is required. Since only a minimal amount of clonidine is removed during routine haemodialysis there is no need to give supplemental clonidine following dialysis.
Sudden withdrawal of Catapres, particularly in those patients receiving high doses, may result in rebound hypertension. Cases of agitation, restlessness, palpitations, nervousness, tremor, headache and abdominal symptoms have also been reported. Patients should be instructed not to discontinue therapy without consulting their physician. When discontinuing therapy the physician should reduce the dose gradually. However, if withdrawal symptoms should nevertheless occur, these can usually be treated with reintroduction of clonidine or with alpha and beta adrenoceptor blocking agents.
If Catapres is being given concurrently with a beta-blocker, Catapres should not be discontinued until several days after the withdrawal of the beta-blocker.
Patients who wear contact lenses should be warned that treatment with Catapres may cause decreased lacrimation.
This product contains 36.1 mg of lactose monohydrate per tablet. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
The use and the safety of clonidine in children and adolescents has little supporting evidence in randomized controlled trials and therefore cannot be recommended for use in this population.
Serious adverse events, including sudden death, have been reported in concomitant use with methylphenidate. The safety of using methylphenidate in combination with clonidine has not been systematically evaluated.
The reduction in blood pressure induced by clonidine can be further potentiated by concurrent administration of other hypotensive agents. This can be of therapeutic use in the case of other antihypertensive agents such as diuretics, vasodilators, beta-receptor blockers, calcium antagonists and ACE-inhibitors, but the effect of alphar blockers is unpredictable.
The antihypertensive effect of clonidine may be reduced or abolished and orthostatic hypotension may be provoked or aggravated by concomitant administration of tricyclic antidepressants or neuroleptics with alpha-receptor blocking properties.
Substances which raise blood pressure or induce a sodium ion (Na+) and water retaining effect such as non-steroidal anti-inflammatory agents can reduce the therapeutic effect of clonidine.
Substances with alpha2-receptor blocking properties, such as mirtazapine, may abolish the alpha2-receptor mediated effects of clonidine in a dose-dependent manner.
Concomitant administration of substances with a negative chronotropic or dromotropic effect such as beta-receptor blockers or digitalis glycosides can cause or potentiate bradycardic rhythm disturbances.
It cannot be ruled out that concomitant administration of a beta-receptor blocker will cause or potentiate peripheral vascular disorders.
Based on observations in patients in a state of alcoholic delirium it has been suggested that high intravenous doses of clonidine may increase the arrhythmogenic potential (QT-prolongation, ventricular fibrillation) of high intravenous doses of haloperidol. Causal relationship and relevance for antihypertensive treatment have not been established.
The effects of centrally depressant substances or alcohol can be potentiated by clonidine.
There are limited amount of data from the use of clonidine in pregnant women. This product should only be used in pregnancy if considered essential by the physician. Careful monitoring of mother and child is recommended.
Clonidine passes the placental barrier and may lower the heart rate of the foetus. Post partum a transient rise in blood pressure in the newborn cannot be excluded.
There is no adequate experience regarding the long-term effects of prenatal exposure.
During pregnancy the oral forms of clonidine should be preferred. Intravenous injection of clonidine should be avoided.
Non-clinical studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.
Clonidine is excreted in human milk. However, there is insufficient information on the effect on newborns. The use of Catapres is therefore not recommended during breastfeeding.
No clinical studies on the effect on human fertility have been conducted with clonidine. Non-clinical studies with clonidine indicate no direct or indirect harmful effects with respect to the fertility index.
No studies on the effects on the ability to drive and use machines have been performed.
However, patients should be advised that they may experience undesirable effects such as dizziness, sedation and accommodation disorder during treatment with Catapres. If patients experience the above mentioned side effects they should avoid potentially hazardous tasks such as driving or operating machinery.
Most adverse effects are mild and tend to diminish with continued therapy.
Adverse events have been ranked under headings of frequency using the following convention:
Very common > 1/10 Common > 1/100, <1/10 Uncommon >1/1000, <1/100 Rare >1/10000, <1/1000
Very rare <1/10000
Not known Cannot be estimated from the available data
not known uncommon common uncommon
not known uncommon common
not known rare
Endocrine disorders: Gynaecomastia
Psychiatric disorders: Confusional state Delusional perception Depression Hallucination Libido decreased Nightmare Sleep disorder
Nervous system disorders:
Eye disorders: Accommodation disorder Lacrimation decreased
Atrioventricular block rare
Bradyarrhythmia not known
Orthostatic hypotension very common
Raynaud's phenomenon uncommon
Respiratory, thoracic and mediastinal disorders: Nasal dryness rare
common very common common common common
Salivary gland pain Vomiting
Skin and subcutaneous tissue disorders: Alopecia Pruritus Rash Urticaria
Reproductive system and breast disorders: Erectile dysfunction common
General disorders and administration site conditions:
Blood glucose increased rare
There are occasional reports of fluid retention during initial stages of oral treatment. This is usually transitory and can be corrected by the addition of a diuretic.
Occasional reports of abnormal liver function tests and two cases of hepatitis have also been reported.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit / risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
Manifestations of intoxication are due to a generalised sympathetic depression and include pupillary constriction, lethargy, bradycardia, hypotension, hypothermia, somnolence including coma and respiratory depression including apnoea. Paradoxical hypertension caused by stimulation of peripheral alpha1-receptors may occur. Transient hypertension may be seen if the total dose is over 10 mg.
There is no specific antidote for clonidine overdose. Administration of activated charcoal should be performed where appropriate.
Supportive care may include atropine sulfate for symptomatic bradycardia, and intravenous fluids and/or inotropic sympathomimetic agents for hypotension. Severe persistent hypertension may require correction with alpha-adrenoceptor blocking drugs.
Naloxone may be a useful adjunct for the management of clonidine-induced respiratory depression.
Catapres has been shown to have both central and peripheral sites of action. With long-term treatment Catapres reduces the responsiveness of peripheral vessels to vasoconstrictor and vasodilator substances and to sympathetic nerve stimulation. Early in treatment, however, blood pressure reduction is associated with a central reduction of sympathetic outflow and increased vagal tone.
Clinically, there may be reduced venous return and slight bradycardia resulting in reduced cardiac output. Although initially peripheral resistance may be unchanged, it tends to be reduced as treatment continues. There is no interference with myocardial contractility. Studies have shown that cardiovascular reflexes, as shown by the lack of postural hypotension and exercise hypotension, are preserved.
The efficacy of clonidine in the treatment of hypertension has been investigated in five clinical studies in paediatric patients. The efficacy data confirms the properties of clonidine in reduction of systolic and diastolic blood pressure. However, due to limited data and methodological insufficiencies, no definitive conclusion can be drawn on the use of clonidine for hypertensive children.
The efficacy of clonidine has also been investigated in a few clinical studies with paediatric patients with ADHD, Tourette syndrome and stuttering. The efficacy of clonidine in these conditions has not been demonstrated.
There were also two small paediatric studies in migraine, neither of which demonstrated efficacy. In the paediatric studies the most frequent adverse events were drowsiness, dry mouth, headache, dizziness and insomnia. These adverse events might have serious impact on daily functioning in paediatric patients.
Overall, the safety and efficacy of clonidine in children and adolescents have not been established (see section 4.2).
Absorption and distribution
The pharmacokinetics of clonidine is dose-proportional in the range of 75-300 micrograms; over this range, dose linearity has not been fully demonstrated. Clonidine, the active ingredient of Catapres, is highly absorbed and undergoes a minor first pass effect. Peak plasma concentrations are reached within 1-3 h after oral administration. The plasma protein binding is 30-40%.
Clonidine is rapidly and extensively distributed into tissues and crosses the blood-brain barrier, as well as the placental barrier. Clonidine is excreted in human milk. However, there is insufficient information on the effect on newborns.
Metabolism and elimination
The terminal elimination half-life of clonidine has been found to range from 5 to 25.5 hours. It can be prolonged in patients with severely impaired renal function up to 41 hours.
About 70% of the dose administered is excreted with the urine mainly in form of the unchanged parent drug (40-60% of the dose). The main metabolite p-hydroxy-clonidine is pharmacologically inactive. Approximately 20% of the total amount is excreted with the faeces. There is no definitive data about food or race effects on the pharmacokinetics of clonidine.
The antihypertensive effect is reached at plasma concentrations between about 0.2 and 2.0 ng/ml in patients with normal renal function. The hypotensive effect is attenuated or decreases with plasma concentrations above 2.0 ng/ml.
There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
Lactose monohydrate,fine Calcium hydrogen phosphate (anhydrous) Maize starch, dried Colloidal silica (anhydrous)
Povidone Soluble starch
Do not store above 30°C.
Keep the blisters in the outer carton
Opaque PVC 250pm thick/PVDC 40 g/m2 blisters with aluminium lidding foil 20pm in packs of 100 tablets.
No special requirements
Boehringer Ingelheim Limited Ellesfield Avenue Bracknell, Berkshire RG12 8YS United Kingdom.
DATE OF REVISION OF THE TEXT